Acar, Celal

Loading...
Profile Picture
Name Variants
Acar, C.
C Acar
Celal Acar
Job Title
Email Address
celal.acar@ieu.edu.tr
Main Affiliation
09.02. Internal Sciences
Status
Current Staff
Website
Scopus Author ID
Turkish CoHE Profile ID
Google Scholar ID
WoS Researcher ID

Sustainable Development Goals

SDG data is not available
Documents

9

Citations

75

h-index

5

Documents

19

Citations

85

Scholarly Output

2

Articles

2

Views / Downloads

4/0

Supervised MSc Theses

0

Supervised PhD Theses

0

WoS Citation Count

0

Scopus Citation Count

0

WoS h-index

0

Scopus h-index

0

Patents

0

Projects

0

WoS Citations per Publication

0.00

Scopus Citations per Publication

0.00

Open Access Source

0

Supervised Theses

0

JournalCount
Journal of Infection in Developing Countries1
The Journal of Infection in Developing Countries1
Current Page: 1 / 1

Scopus Quartile Distribution

Competency Cloud

GCRIS Competency Cloud

Scholarly Output Search Results

Now showing 1 - 2 of 2
  • Article
    Fungal Sinusitis Due To Mucormycosis in a Diabetic Immunosuppressed Patient With Acute Myeloid Leukemia (AML)
    (J infection Developing Countries, 2024) Ece, Gulfem; Ciger, Ejder; Acar, Celal; Cagirgan, Seckin; Cetin, Ogulcan
    Introduction: Mucormycosis is an acute onset, invasive, fungal infection, characterized by organ involvement, and caused by Mucor, Rhizopus, or Absidia. Our aim was to present a case of mucormycotic infection and emphasize its importance in a diabetic immunosuppressed patient with acute myeloid leukemia (AML). Case presentation: A 68-year-old hypertensive and diabetic male patient with a diagnosis of AML developed respiratory failure and exhibited diffuse bilateral consolidation in high-resolution computed tomography (HRCT). The treatment plan involved chemotherapy with cytarabine (200 mg/m2/day for 7 days) and daunorubicin (60 mg/m2/day for 3 days) starting on 20 July 2022. Posaconazole prophylactic treatment was initiated on 23 July 2022, to prevent fungal infections. Five days later there was a black necrotic appearance on the left wing of the nose. The patient underwent excision of the left wing of the nose. Mucor was detected in the excision tissue both histopathologically and in culture. A culture under lactophenol cotton blue (LFCB) staining displaying hyphal structures of Mucor was obtained. The patient died of progressive pneumonia and sepsis. Conclusions: Mucormycosis is an infection with high mortality, and should be considered in the early stages of diagnosis when dealing with immunosuppression patients.
  • Article
    Fungal Sinusitis Due To Mucormycosis in a Diabetic Immunosuppressed Patient With Acute Myeloid Leukemia (aml)
    (Journal of Infection in Developing Countries, 2024) Ece, G.; Ciger, E.; Acar, C.; Cagirgan, S.; Cetin, O.
    Introduction: Mucormycosis is an acute onset, invasive, fungal infection, characterized by organ involvement, and caused by Mucor, Rhizopus, or Absidia. Our aim was to present a case of mucormycotic infection and emphasize its importance in a diabetic immunosuppressed patient with acute myeloid leukemia (AML). Case presentation: A 68-year-old hypertensive and diabetic male patient with a diagnosis of AML developed respiratory failure and exhibited diffuse bilateral consolidation in high-resolution computed tomography (HRCT). The treatment plan involved chemotherapy with cytarabine (200 mg/m2/day for 7 days) and daunorubicin (60 mg/m2/day for 3 days) starting on 20 July 2022. Posaconazole prophylactic treatment was initiated on 23 July 2022, to prevent fungal infections. Five days later there was a black necrotic appearance on the left wing of the nose. The patient underwent excision of the left wing of the nose. Mucor was detected in the excision tissue both histopathologically and in culture. A culture under lactophenol cotton blue (LFCB) staining displaying hyphal structures of Mucor was obtained. The patient died of progressive pneumonia and sepsis. Conclusions: Mucormycosis is an infection with high mortality, and should be considered in the early stages of diagnosis when dealing with immunosuppression patients. Copyright © 2024 Ece et al.